Tango Therapeutics (NASDAQ:TNGX) Director Sells $374,162.94 in Stock

Tango Therapeutics, Inc. (NASDAQ:TNGX) Director Barbara Weber sold 30,519 shares of the firm’s stock in a transaction that occurred on Tuesday, February 3rd. The shares were sold at an average price of $12.26, for a total transaction of $374,162.94. Following the transaction, the director owned 1,629,254 shares in the company, valued at $19,974,654.04. This represents a 1.84% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website.

Tango Therapeutics Price Performance

Shares of NASDAQ:TNGX opened at $12.51 on Friday. The stock has a market cap of $1.68 billion, a price-to-earnings ratio of -13.45 and a beta of 1.75. Tango Therapeutics, Inc. has a 12 month low of $1.03 and a 12 month high of $13.46. The stock’s 50 day moving average price is $10.40 and its 200 day moving average price is $8.59.

Tango Therapeutics (NASDAQ:TNGX) last issued its quarterly earnings results on Tuesday, November 4th. The company reported $0.13 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.01 by $0.12. Tango Therapeutics had a negative return on equity of 60.80% and a negative net margin of 151.15%.The company had revenue of $53.81 million for the quarter, compared to analysts’ expectations of $41.35 million. On average, sell-side analysts expect that Tango Therapeutics, Inc. will post -1.19 EPS for the current year.

Hedge Funds Weigh In On Tango Therapeutics

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Global Retirement Partners LLC acquired a new stake in Tango Therapeutics during the 4th quarter valued at $35,000. Zurcher Kantonalbank Zurich Cantonalbank grew its holdings in shares of Tango Therapeutics by 148,800.0% during the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 4,467 shares of the company’s stock valued at $40,000 after buying an additional 4,464 shares in the last quarter. ANTIPODES PARTNERS Ltd acquired a new position in Tango Therapeutics during the fourth quarter valued at $40,000. CWM LLC raised its position in Tango Therapeutics by 182.2% during the second quarter. CWM LLC now owns 4,905 shares of the company’s stock valued at $25,000 after buying an additional 3,167 shares during the period. Finally, Mirae Asset Global Investments Co. Ltd. lifted its stake in Tango Therapeutics by 52.2% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 6,544 shares of the company’s stock worth $58,000 after acquiring an additional 2,243 shares in the last quarter. Institutional investors and hedge funds own 78.99% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages have weighed in on TNGX. Cantor Fitzgerald reissued an “overweight” rating on shares of Tango Therapeutics in a report on Monday, October 27th. Piper Sandler boosted their target price on shares of Tango Therapeutics from $11.00 to $14.00 and gave the stock an “overweight” rating in a report on Friday, January 16th. Wall Street Zen raised shares of Tango Therapeutics from a “hold” rating to a “buy” rating in a research note on Saturday, December 13th. Stifel Nicolaus started coverage on shares of Tango Therapeutics in a research report on Wednesday, December 3rd. They issued a “buy” rating and a $15.00 price target on the stock. Finally, Guggenheim upped their price target on Tango Therapeutics from $12.00 to $18.00 and gave the company a “buy” rating in a report on Friday. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $14.80.

Tango Therapeutics Company Profile

Tango Therapeutics is a clinical-stage biotechnology company dedicated to developing precision medicines that exploit genetic vulnerabilities in cancer cells. Leveraging a proprietary synthetic lethality platform, the company identifies and targets tumor-specific dependencies in DNA damage response and related pathways. By focusing on tumor cell collateral sensitivities, Tango aims to bring differentiated small-molecule therapies to patients with genetic alterations that confer increased susceptibility to targeted inhibition.

The company’s lead pipeline comprises several early-stage programs, including inhibitors designed to selectively disable DNA repair proteins in tumor cells while sparing normal tissues.